|
1
|
Robinson BW, Musk AW and Lake RA:
Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roggli VL, Sharma A, Butnor KJ, Sporn T
and Vollmer RT: Malignant mesothelioma and occupational exposure to
asbestos: A clinicopathological correlation of 1445 cases.
Ultrastruct Pathol. 26:55–65. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delgermaa V, Takahashi K, Park EK, Le GV,
Hara T and Sorahan T: Global mesothelioma deaths reported to the
World Health Organization between 1994 and 2008. Bull World Health
Organ. 89:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Murayama T, Takahashi K, Natori Y and
Kurumatani N: Estimation of future mortality from pleural malignant
mesothelioma in Japan based on an age-cohort model. Am J Ind Med.
49:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Churg A, Roggli V, Galateau-Salle F, Cagle
PhT, Gibbs AR, Hasleton PhS, Henderson DW, Vignaud JM, Inai K,
Praet M, et al: Tumours of the pleuraWHO Classification of Tumours
of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E,
Burke AP, Marx A and Nicholson AG: IARC Press; Lyon: pp. 153–181.
2015
|
|
6
|
Husain AN, Colby T, Ordonez N, Krausz T,
Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac
LR, et al: Guidelines for pathologic diagnosis of malignant
mesothelioma: 2012 update of the consensus statement from the
International Mesothelioma Interest Group. Arch Pathol Lab Med.
137:647–667. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ordóñez NG: Application of
immunohistochemistry in the diagnosis of epithelioid mesothelioma:
A review and update. Hum Pathol. 44:1–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kushitani K, Amatya VJ, Okada Y, Katayama
Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T and Takeshima
Y: Utility and pitfall of immunohistochemistry in the differential
diagnosis between epithelioid mesothelioma and poorly
differentiated lung squamous cell carcinoma. Histopathology.
70:375–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minato H, Kurose N, Fukushima M, Nojima T,
Usuda K, Sagawa M, Sakuma T, Ooi A, Matsumoto I, Oda M, et al:
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA,
CD146, and desmin for distinguishing malignant mesothelioma from
reactive mesothelial cells. Am J Clin Pathol. 141:85–93. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hida T, Hamasaki M, Matsumoto S, Sato A,
Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H and
Nabeshima K: BAP1 immunohistochemistry and p16 FISH results in
combination provide higher confidence in malignant pleural
mesothelioma diagnosis: ROC analysis of the two tests. Pathol Int.
66:563–570. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hwang HC, Sheffield BS, Rodriguez S,
Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1
immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of
malignant mesothelioma in effusion cytology specimens. Am J Surg
Pathol. 40:120–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McGregor SM, Dunning R, Hyjek E,
Vigneswaran W, Husain AN and Krausz T: BAP1 facilitates diagnostic
objectivity, classification, and prognostication in malignant
pleural mesothelioma. Hum Pathol. 46:1670–1678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cigognetti M, Lonardi S, Fisogni S,
Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G,
Murer B, et al: BAP1 (BRCA1-associated protein 1) is a highly
specific marker for differentiating mesothelioma from reactive
mesothelial proliferations. Mod Pathol. 28:1043–1057. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kimura F, Okayasu I, Kakinuma H, Satoh Y,
Kuwao S, Saegusa M and Watanabe J: Differential diagnosis of
reactive mesothelial cells and malignant mesothelioma cells using
the cell proliferation markers minichromosome maintenance protein
7, geminin, topoisomerase II alpha and Ki-67. Acta Cytol.
57:384–390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kimura F, Kawamura J, Watanabe J,
Kamoshida S, Kawai K, Okayasu I and Kuwao S: Significance of cell
proliferation markers (Minichromosome maintenance protein 7,
topoisomerase IIalpha and Ki-67) in cavital fluid cytology: Can we
differentiate reactive mesothelial cells from malignant cells?
Diagn Cytopathol. 38:161–167. 2010.PubMed/NCBI
|
|
16
|
Hasteh F, Lin GY, Weidner N and Michael
CW: The use of immunohistochemistry to distinguish reactive
mesothelial cells from malignant mesothelioma in cytologic
effusions. Cancer Cytopathol. 118:90–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taheri ZM, Mehrafza M, Mohammadi F,
Khoddami M, Bahadori M and Masjedi MR: The diagnostic value of
Ki-67 and repp86 in distinguishing between benign and malignant
mesothelial proliferations. Arch Pathol Lab Med. 132:694–697.
2008.PubMed/NCBI
|
|
18
|
Churg A, Sheffield BS and Galateau-Salle
F: New markers for separating benign from malignant mesothelial
proliferations: Are we there yet? Arch Pathol Lab Med. 140:318–321.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiroshima K, Wu D, Hasegawa M, Koh E,
Sekine Y, Ozaki D, Yusa T, Walts AE, Marchevsky AM, Nabeshima K, et
al: Cytologic differential diagnosis of malignant mesothelioma and
reactive mesothelial cells with fish analysis of p16. Diagn
Cytopathol. 44:591–598. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Walts AE, Hiroshima K, McGregor SM, Wu D,
Husain AN and Marchevsky AM: BAP1 immunostain and CDKN2A (p16) FISH
analysis: Clinical applicability for the diagnosis of malignant
mesothelioma in effusions. Diagn Cytopathol. 44:599–606. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kushitani K, Amatya VJ, Mawas AS, Miyata
Y, Okada M and Takeshima Y: Use of anti-noxa antibody for
differential diagnosis between epithelioid mesothelioma and
reactive mesothelial hyperplasia. Pathobiology. 83:33–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
Classification of Lung Tumors: Impact of genetic, clinical and
radiologic advances since the 2004 classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Garg H, Suri P, Gupta JC, Talwar GP and
Dubey S: Survivin: A unique target for tumor therapy. Cancer Cell
Int. 16:492016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Meerang M, Bérard K, Friess M, Bitanihirwe
BK, Soltermann A, Vrugt B, Felley-Bosco E, Bueno R, Richards WG,
Seifert B, et al: Low merlin expression and high survivin labeling
index are indicators for poor prognosis in patients with malignant
pleural mesothelioma. Mol Oncol. 10:1255–1265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hmeljak J, Erčulj N, Dolžan V, Pižem J,
Kern I, Kovač V, Cemažar M and Cör A: Is survivin expression
prognostic or predictive in malignant pleural mesothelioma?
Virchows Arch. 462:315–321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen S, Wang Y, An L, Fei ZT and Li T: The
diagnostic value of survivin in malignant pleural effusion: A
meta-analysis. Clin Chim Acta. 441:142–147. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bertino P, Panigada M, Soprana E, Bianchi
V, Bertilaccio S, Sanvito F, Rose AH, Yang H, Gaudino G, Hoffmann
PR, et al: Fowlpox-based survivin vaccination for malignant
mesothelioma therapy. Int J Cancer. 133:612–623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Cesare M, Cominetti D, Doldi V,
Lopergolo A, Deraco M, Gandellini P, Friedlander S, Landesman Y,
Kauffman MG, Shacham S, et al: Anti-tumor activity of selective
inhibitors of XPO1/CRM1-mediated nuclear export in diffuse
malignant peritoneal mesothelioma: The role of survivin.
Oncotarget. 6:13119–13132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goričar K, Kovač V, Franko A, Dodič-Fikfak
M and Dolžan V: Serum survivin levels and outcome of chemotherapy
in patients with malignant mesothelioma. Dis Markers.
2015:3167392015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Murali R, Wiesner T and Scolyer RA:
Tumours associated with BAP1 mutations. Pathology. 45:116–126.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scheuermann JC, de Ayala Alonso AG, Oktaba
K, Ly-Hartig N, McGinty RK, Fraterman S, Wilm M, Muir TW and Müller
J: Histone H2A deubiquitinase activity of the Polycomb repressive
complex PR-DUB. Nature. 465:243–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bott M, Brevet M, Taylor BS, Shimizu S,
Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, et al: The
nuclear deubiquitinase BAP1 is commonly inactivated by somatic
mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat
Genet. 43:668–672. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Testa JR, Cheung M, Pei J, Below JE, Tan
Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, et al: Germline
BAP1 mutations predispose to malignant mesothelioma. Nat Genet.
43:1022–1025. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yoshikawa Y, Sato A, Tsujimura T, Emi M,
Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S,
et al: Frequent inactivation of the BAP1 gene in epithelioid-type
malignant mesothelioma. Cancer Sci. 103:868–874. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shinozaki-Ushiku A, Ushiku T, Morita S,
Anraku M, Nakajima J and Fukayama M: Diagnostic utility of BAP1 and
EZH2 expression in malignant mesothelioma. Histopathology.
70:722–733. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Brown DC and Gatter KC: Monoclonal
antibody Ki-67: Its use in histopathology. Histopathology.
17:489–503. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Altieri DC: Validating survivin as a
cancer therapeutic target. Nat Rev Cancer. 3:46–54. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kim JY, Chung JY, Lee SG, Kim YJ, Park JE,
Yoo KS, Yoo YH, Park YC, Kim BG and Kim JM: Nuclear interaction of
Smac/DIABLO with survivin at G2/M arrest prompts docetaxel-induced
apoptosis in DU145 prostate cancer cells. Biochem Biophys Res
Commun. 350:949–954. 2006. View Article : Google Scholar : PubMed/NCBI
|
